Template:Second-generation BTKi table

Second-generation Bruton’s Tyrosine Kinase Inhibitors (BTKi) for CCL Treatment

BTK inhibitor	BTK binding mechanism	Selectivity for BTK	Relevant non-BTK targets	Clinical Phase
Acalabrutinib	Covalent, irreversible	High	N/A	II/III
Zanubrutinib	Covalent, irreversible	Moderate	N/A	II/III
Tirabrutinib	Covalent, irreversible	High	N/A	I/II
Vecabrutinib	Non-covalent, reversible	Moderate	interleukin-2-inducible (ITK)	I/II
LOXO-305	Non-covalent, reversible	High	N/A	I
ARQ-531	Non-covalent, reversible	Low	Lck/Yes novel tyrosine kinase (LYN), mitogen-activated protein kinase kinase 1 (MEK1)	I
Table data